IDNA iShares Genomics Immunology and Healthcare ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 41.48 | Day Range | 40.58 – 41.07 |
| 52-Week Range | 22.12 – 41.49 | Volume | 184.15K |
| Avg Volume | 55.71K | AUM | $258.5M (Aug 27, 2026) |
| Expense Ratio | 0.47% | Yield (TTM) | 0.69% |
| NAV | 41.36 | Premium/Discount | -1.76% indicative |
| Inception | Jun 11, 2019 | Holdings | 50 |
| Issuer | iShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 46435U192 | ISIN | US46435U1925 |
| Management | Not stated in source data | ||
About this ETF
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to mirror the investment performance of a specific index. This index comprises companies operating in both mature and emerging global markets. These businesses are strategically chosen for their potential to capitalize on sustained innovation and expansion within the crucial fields of genomics, immunology, and bioengineering.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +26.02% | +36.30% | +31.92% | +55.14% | +81.63% | +22.81% | -5.42% | — | +7.21% |
| Total return | +26.02% | +36.85% | +32.47% | +55.79% | +83.51% | +24.22% | -4.52% | — | +8.11% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 26, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.47% | Annual cost of a $10,000 investment | $47.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 61 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | MODERNA INC | MRNA | 8.38% | 154.46K | $20.6M |
| 2 | TWIST BIOSCIENCE | TWST | 5.87% | 105.86K | $14.4M |
| 3 | REVOLUTION MEDICINES | RVMD | 4.23% | 49.10K | $10.4M |
| 4 | BAYER AG | BAYN.DE | 4.05% | 175.32K | $10.0M |
| 5 | GENMAB | GMAB.CO | 4.05% | 29.73K | $9.9M |
| 6 | REGENERON PHARMACEUTICALS | REGN | 3.88% | 11.53K | $9.5M |
| 7 | BIONTECH SE ADR | BNTX | 3.75% | 83.19K | $9.2M |
| 8 | INCYTE CORP | INCY | 3.70% | 71.57K | $9.1M |
| 9 | MERCK & CO INC | MRK | 3.68% | 60.66K | $9.0M |
| 10 | VERTEX PHARMACEUTICALS | VRTX | 3.60% | 16.40K | $8.9M |
| 11 | TAKEDA PHARMACEUTICAL | 4502.T | 3.56% | 238.40K | $8.7M |
| 12 | ROCHE PS PAR AG | ROP.SW | 3.37% | 17.79K | $8.3M |
| 13 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 3.26% | 891.77K | $8.0M |
| 14 | IPSEN SA | IPN.PA | 3.12% | 40.17K | $7.7M |
| 15 | IDEAYA BIOSCIENCES | IDYA | 3.04% | 191.19K | $7.5M |
| 16 | EXELIXIS INC | EXEL | 3.04% | 139.06K | $7.5M |
| 17 | GLAXOSMITHKLINE | GSK.L | 3.01% | 282.48K | $7.4M |
| 18 | SANOFI SA | SAN.PA | 3.01% | 81.34K | $7.4M |
| 19 | CARIS LIFE SCIENCES | CAI | 2.82% | 281.92K | $6.9M |
| 20 | IMMUNITYBIO INC | IBRX | 2.76% | 865.66K | $6.8M |
| 21 | ABCELLERA BIOLOGICS | ABCL | 2.54% | 539.13K | $6.2M |
| 22 | ARCUS BIOSCIENCES | RCUS | 2.31% | 192.54K | $5.7M |
| 23 | ONO PHARMACEUTICAL | 4528.T | 1.64% | 258.50K | $4.0M |
| 24 | NUVATION BIO CLASS A | NUVB | 1.58% | 568.09K | $3.9M |
| 25 | CRISPR THERAPEUTICS AG | CRSP | 1.56% | 65.94K | $3.8M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.69% | Paid (last 12 months) | $0.2809 |
| Frequency | Semi-Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 15, 2026 | Last payment | $0.1254 (Jun 18, 2026) |
| Growth 1Y | +6.41% | Growth 3Y / 5Y (ann.) | +58.33% / +26.07% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.1254 |
| Dec 16, 2025 | Dec 16, 2025 | Dec 19, 2025 | $0.1555 |
| Jun 16, 2025 | Jun 16, 2025 | Jun 20, 2025 | $0.1529 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 20, 2024 | $0.1110 |
| Jun 11, 2024 | Jun 11, 2024 | Jun 17, 2024 | $0.1114 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.1693 |
| Jun 07, 2023 | Jun 08, 2023 | Jun 13, 2023 | $0.0708 |
| Jun 09, 2022 | Jun 10, 2022 | Jun 15, 2022 | $0.1360 |
| Dec 13, 2021 | Dec 14, 2021 | Dec 17, 2021 | $0.2564 |
| Jun 10, 2021 | Jun 11, 2021 | Jun 16, 2021 | $0.0520 |
| Dec 14, 2020 | Dec 15, 2020 | Dec 18, 2020 | $0.0362 |
| Jun 15, 2020 | Jun 16, 2020 | Jun 19, 2020 | $0.0837 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 28.36% / 26.27% | Sharpe 1Y / 3Y | 3.09 / 0.952 |
| Max drawdown 1Y / 3Y | -10.65% / -29.45% | Sortino 1Y | 5.68 |
| Beta vs S&P 500 (3Y) | 0.903 | Correlation vs S&P 500 (1Y) | 0.421 |
| Downside deviation 1Y | 15.41% | Risk-free rate used | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 27, 2026. Formulas →
Liquidity
| Volume today | 184.15K | Average volume | 55.71K |
| AUM | $258.5M | Premium/Discount | -1.76% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $258.5M → $258.5M |
| 1 Week | $32.2M | +14.69% | $218.9M → $258.5M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for IDNA
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.